Hemophilia treatment market is driven by aging populations increasing acquired cases, government-backed early diagnosis, and ...

The purpose of this gene therapy is for those people living with haemophilia B, once treated, to be able to produce FIX via the treatment (a one-time treatment), rather than having to receive ...

There will soon be two gene therapies available for patients with haemophilia B in the EU after the European Commission approved Pfizer's fidanacogene elaparvovec under the Durveqtix brand name.

The arc of biotechnology is one of breakthroughs and struggles, writes Tim Hunt, CEO of the Alliance for Regenerative ...

There has been a gene therapy on the market for people with the bleeding disorder haemophilia A since 2022, but take-up has been very slow. Pfizer and Sangamo are hoping for a faster trajectory ...

It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark. In the UK, health technology ...

Anxious not to be left behind in the haemophilia market, Novo Nordisk has forged an alliance with Bluebird Bio to apply a gene-editing approach to the bleeding disorder. The two partners have ...

In another sign of the challenges facing gene therapy developers, Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.

CSL and uniQure’s gene therapy for haemophilia B has been approved by the European Commission, ushering in a new era of therapy for patients with the bleeding disorder in the EU. The therapy has ...

BioMarin Pharma has its landmark first approval for Roctavian – the first for a haemophilia gene therapy – and will now have to see if that can convert that into a viable business in Europe.

The hemophilia treatment landscape is rapidly evolving, with newly launched therapies and gene therapies joining factor replacement therapies, Hemlibra, and Altuvio to ...